Tuftsin

What is Tuftsin?

Tuftsin is a four-amino-acid peptide with the sequence Thr-Lys-Pro-Arg (TKPR) corresponding to residues 289-292 of the CH2 domain of the IgG heavy chain Fc region. It is generated in vivo by sequential proteolytic cleavage of an immunoglobulin precursor: a splenic enzyme historically called leukokininase makes the C-terminal cut between residues 292 and 293, and a leukocyte-membrane enzyme called tuftsin-endocarboxypeptidase releases the free tetrapeptide by cutting between residues 288 and 289. The peptide was discovered in 1970 by Victor A. Najjar and Kazuhiko Nishioka at Tufts University School of Medicine in Boston, who named it 'tuftsin' after their institution. Functionally, tuftsin is one of the prototypical phagocyte-stimulating peptides: it binds receptors on macrophages, monocytes, microglia, and polymorphonuclear leukocytes and increases phagocytic activity, chemotaxis, oxidative burst, antibody-dependent cell-mediated cytotoxicity, and bactericidal activity. Neuropilin-1 (Nrp1) was proposed and then formally established as a tuftsin receptor by Stella Tsirka's laboratory at Stony Brook in 2013, with downstream signaling through the transforming growth factor beta pathway and a polarization shift of macrophages and microglia toward an anti-inflammatory M2 phenotype. Tuftsin has never been developed as an approved therapeutic, but it has anchored a long-running research literature on phagocyte pharmacology, post-splenectomy immune dysfunction, tuftsin-conjugated drug delivery (anticancer, antimicrobial, gene delivery), and — more recently — tuftsin-phosphorylcholine, a hybrid molecule modeled on a helminth-derived motif and explored by the Yehuda Shoenfeld group as an experimental treatment for autoimmune disease.

What Tuftsin Is Investigated For

Tuftsin is a research peptide and a textbook entry, not a consumer product. Its scientific footprint sits in three buckets. First, basic immunology: tuftsin is one of the canonical phagocyte-stimulating peptides, and the 1970-1990 literature established that it increases macrophage and PMN phagocytosis, chemotaxis, antibody-dependent cytotoxicity, and microbicidal activity in vitro and in animal models. Second, clinical immunology: 'tuftsin deficiency syndrome' was proposed by Najjar's group in the 1970s and 1980s as a mechanistic explanation for the increased susceptibility to encapsulated-organism sepsis seen in asplenic and post-splenectomy patients, with a small subset of rare congenital tuftsin-deficient cases described. Tuftsin replacement was tested in animal models of post-splenectomy sepsis with positive signals but never advanced to a controlled clinical therapeutic. Third, drug development: because tuftsin is a small, well-tolerated, phagocyte-targeting motif, it has been used as a conjugation handle for anticancer chemotherapeutics, antimicrobials, and nucleic-acid delivery vehicles aiming for tumor-associated macrophages or infected phagocytes. The most active modern thread is tuftsin-phosphorylcholine (TPC), a hybrid molecule that combines the tuftsin scaffold with the phosphorylcholine head group found on parasitic helminth glycans, developed by Miri Blank and Yehuda Shoenfeld at Sheba Medical Center as an experimental treatment for autoimmune disease — efficacy has been shown in preclinical models of arthritis, lupus, and colitis, but no approved product exists. The honest framing is that tuftsin is a well-characterized immunomodulatory motif of high mechanistic interest and modest translational achievement after fifty-five years of study.

History & Discovery

Tuftsin was identified, sequenced, and named in 1970 by Victor A. Najjar and Kazuhiko Nishioka at Tufts University School of Medicine in Boston, who reported the work in a brief but influential Nature paper that November. Najjar had been studying a high-molecular-weight 'leukokinin' fraction of plasma immunoglobulin that stimulated phagocytosis in polymorphonuclear leukocytes, and the 1970 paper pinned the activity to a four-residue peptide — Thr-Lys-Pro-Arg — released from the precursor. The team named the peptide 'tuftsin' after their institution. Subsequent work over the 1970s mapped the peptide to residues 289-292 of the CH2 domain of the IgG heavy chain, characterized the splenic enzyme leukokininase and the leukocyte-membrane enzyme tuftsin-endocarboxypeptidase responsible for the two cleavage steps, and worked out the in vitro pharmacology on phagocytic uptake, chemotaxis, antibody-dependent cytotoxicity, and bactericidal activity. The clinical-immunology angle developed in parallel. Najjar's group proposed in the late 1970s and early 1980s that surgical splenectomy reduces circulating tuftsin (because splenic leukokininase is required for the C-terminal cleavage) and that this 'acquired tuftsin deficiency' contributes to the well-known increased risk of encapsulated-organism sepsis in asplenic patients. A small number of rare congenital tuftsin-deficiency cases were also described. Tuftsin-replacement experiments in animal models of post-splenectomy sepsis (Chu, Nishioka, and colleagues, Surgery 1985) showed positive signals but did not advance to controlled clinical therapeutic development. Drug development through the 1980s and 1990s pursued tuftsin analogs and tuftsin-conjugated cytotoxics, antimicrobials, and gene-delivery vehicles aimed at phagocyte-rich tissue. The receptor question — which proteins on phagocytes actually bind tuftsin — remained unresolved for decades, with multiple candidate receptors proposed and not definitively validated. The modern era opened in 2012-2013 when Stella Tsirka's laboratory at Stony Brook University published a sequence of papers establishing that tuftsin polarizes macrophages and microglia toward an anti-inflammatory M2 phenotype (Wu, Nissen, Chen, Tsirka, PLOS ONE 2012) and that the relevant receptor is neuropilin-1, with downstream signaling through transforming growth factor beta (Nissen, Selwood, Tsirka, Journal of Neurochemistry 2013). The Nrp1 finding revitalized interest in tuftsin as a CNS-relevant immunomodulator and was followed by demonstration that Nrp1 is required for tuftsin's effects in experimental autoimmune encephalomyelitis (Nissen and Tsirka, Glia 2016). The most active recent thread is tuftsin-phosphorylcholine (TPC), developed by Miri Blank, Yehuda Shoenfeld, and colleagues at Sheba Medical Center in Israel. TPC fuses the tuftsin tetrapeptide with phosphorylcholine, a chemical group displayed on parasitic helminth glycans implicated in the immunomodulatory effects helminths exert on their hosts — a hygiene-hypothesis-inspired design. TPC has shown efficacy in mouse models of rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, colitis, and giant-cell arteritis, with effects on regulatory T-cell expansion, B-cell modulation, and gut-microbiota composition. As of 2026, no tuftsin-based therapeutic — parent peptide or analog — has reached approval for any indication.

How It Works

Antibodies are big Y-shaped proteins your immune system makes to flag invaders. Tuftsin is a tiny four-letter snippet hidden inside the antibody. When your spleen and white blood cells chop the antibody at just the right two places, they release this tiny piece — and it acts as a pep talk for your phagocytes (the white blood cells that eat bacteria and debris). It tells them to crawl toward trouble, swallow more bacteria, and kill them faster. People who lose their spleen lose part of the machinery that releases tuftsin, which is one reason they get serious infections more easily. Researchers have explored using synthetic tuftsin and tuftsin hybrids as drugs, but nothing has been approved.

Tuftsin is the tetrapeptide Thr-Lys-Pro-Arg, corresponding to residues 289-292 of the CH2 domain of the IgG heavy chain Fc region. The peptide is liberated by two sequential proteolytic events. Leukokininase, an enzyme localized to the spleen, makes the C-terminal cut between residues 292 (Arg) and 293, generating an immunoglobulin fragment that carries the tuftsin sequence at its C-terminus. Tuftsin-endocarboxypeptidase, a leukocyte-membrane enzyme, then makes the N-terminal cut between residues 288 and 289 (Thr) to release the free tetrapeptide directly onto the phagocyte surface. The dependence on splenic leukokininase is the biochemical basis for the post-splenectomy reduction in circulating tuftsin first described by Najjar's group. Tuftsin's classical pharmacology, established between 1970 and the late 1980s, is phagocyte stimulation. Exogenous tuftsin increases phagocytic uptake of bacteria, yeast, and antibody-coated targets by macrophages, monocytes, and polymorphonuclear leukocytes; increases chemotactic migration toward inflammatory mediators; potentiates antibody-dependent cell-mediated cytotoxicity; and increases bactericidal and tumoricidal activity. Effective concentrations are in the nanomolar to low-micromolar range, with bell-shaped dose-response curves typical of peptide immunomodulators. The receptor question was unresolved for decades. A specific high-affinity tuftsin binding site on phagocytes was repeatedly described in radioligand-binding studies, and several candidate receptors were proposed without definitive validation. The current best-supported answer comes from Stella Tsirka's laboratory at Stony Brook University: in a 2013 Journal of Neurochemistry paper, Nissen, Selwood, and Tsirka demonstrated that tuftsin binds neuropilin-1 (Nrp1) on macrophages and microglia, with downstream signaling through the transforming growth factor beta pathway and Smad-dependent gene expression. The Nrp1-TGF-beta axis underlies tuftsin's documented anti-inflammatory polarization of macrophages and microglia toward an M2 phenotype, characterized in multiple-sclerosis-relevant models of experimental autoimmune encephalomyelitis (Wu, Nissen, Chen, Tsirka, PLOS ONE 2012; Nissen and Tsirka, Glia 2016). The Nrp1-binding model also reconciles tuftsin's effects on microglia, which had previously been difficult to fit into a phagocyte-centric framework. Drug-development applications fall into two threads. First, tuftsin-conjugated drug delivery uses the peptide as a phagocyte-targeting motif: cytotoxic agents, antimicrobials, and nucleic-acid payloads are coupled to tuftsin or tuftsin analogs to deliver cargo selectively to tumor-associated macrophages or to infected phagocytes. Second, tuftsin-phosphorylcholine (TPC), a hybrid molecule combining the tuftsin scaffold with the phosphorylcholine head group found on parasitic helminth glycans, has been developed by Blank, Shoenfeld, and colleagues as an experimental immunomodulator for autoimmune disease, with effects on regulatory T-cell expansion, B-cell function, and gut-microbiota composition demonstrated in mouse models of arthritis, lupus, antiphospholipid syndrome, and colitis. Neither thread has produced an approved product as of 2026.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Tuftsin:

• 01Whether tuftsin's net effect on macrophage and microglial polarization is reliably anti-inflammatory across disease contexts, or whether the M2-skewing phenotype seen in experimental autoimmune encephalomyelitis is paradigm-specific and reverses in other inflammatory settings.
• 02Whether the post-splenectomy reduction in circulating tuftsin is clinically meaningful relative to other splenic immune functions (memory B cells, opsonization, filtration of encapsulated organisms) — and whether tuftsin replacement would add value over current post-splenectomy vaccination and prophylaxis.
• 03Whether tuftsin-conjugated drug-delivery constructs targeting tumor-associated macrophages or infected phagocytes can achieve a therapeutic index superior to non-targeted versions of the same payloads in human disease.
• 04Whether tuftsin-phosphorylcholine will reproduce its preclinical autoimmunity efficacy in controlled human trials, and which indication (rheumatoid arthritis, lupus, antiphospholipid syndrome, colitis, giant-cell arteritis) would be the most tractable first registration path.
• 05Whether neuropilin-1 is the only physiologically relevant tuftsin receptor or whether additional binding partners account for some of the tuftsin pharmacology not fully explained by the Nrp1-TGF-beta axis.
• 06Whether the rare congenital tuftsin-deficiency syndromes described in older literature represent a distinct genetic disorder or a heterogeneous group of immunoglobulin-processing defects that incidentally affect tuftsin release.
• 07Whether tuftsin or analogs have a defensible role in central-nervous-system disease (Alzheimer's-relevant microglial dysfunction, multiple sclerosis, intracerebral hemorrhage) given the documented Nrp1-driven anti-inflammatory polarization in preclinical models.

Forms & Administration

Tuftsin is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic Thr-Lys-Pro-Arg as a reference standard for in vitro phagocyte assays, ex vivo tissue pharmacology, and animal-model administration (typically intraperitoneal, intravenous, or intracerebroventricular depending on study). Tuftsin-conjugated drug-delivery systems exist as investigational research tools, with peptide cargos coupled via lysine or arginine side chains. Tuftsin-phosphorylcholine is administered intraperitoneally or orally in mouse autoimmunity models. Compounded or reference-grade tuftsin sold through peptide-marketplace channels has no validated clinical use, no quality-controlled dosing protocol, and no human safety dataset to support self-administration.

Common Questions

Who Tuftsin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for tuftsin because no tuftsin product has been clinically developed beyond small dated investigative-use studies. Theoretical interactions follow from tuftsin's known pharmacology. Phagocyte activation could in principle modulate the activity of antimicrobial agents (potentiating bacterial clearance during macrophage- and PMN-mediated host defense) and of cytotoxic chemotherapeutics that depend on tumor-associated macrophage function, including agents whose efficacy is sensitive to M1/M2 polarization state. Co-administration with immunosuppressive agents (corticosteroids, calcineurin inhibitors, biologics) would have unpredictable directional effects given that tuftsin's net immunological output depends on disease and tissue context. The Nrp1-TGF-beta downstream signaling means tuftsin activity could in principle interact with other Nrp1-targeting agents (some VEGF-pathway and antiangiogenic compounds) or TGF-beta-pathway-targeted therapies. None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities that argue against casual exogenous tuftsin exposure rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions